Jenny P. Ting also specializes in developing a STING agonist delivery platform, new STING agonist compounds, and influenza vaccines (Watkins-Schulz et al., 2019; Gallovic et al., 2022; Yang et al., 2022). Here, STING1 is linked to influenza.